Saltar al contenido
Merck

SML0289

Sigma-Aldrich

Bromfenac sodium

≥98% (HPLC)

Sinónimos:

2-Amino-3-(4-bromobenzoyl)benzeneacetic acid sodium salt

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C15H11BrNNaO3
Número de CAS:
Peso molecular:
356.15
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
En este momento no podemos mostrarle ni los precios ni la disponibilidad

Quality Level

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

faintly yellow to dark yellow

solubility

H2O: ≥5 mg/mL

storage temp.

2-8°C

SMILES string

[Na+].Nc1c(CC([O-])=O)cccc1C(=O)c2ccc(Br)cc2

InChI

1S/C15H12BrNO3.Na/c16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19;/h1-7H,8,17H2,(H,18,19);/q;+1/p-1

InChI key

HZFGMQJYAFHESD-UHFFFAOYSA-M

Gene Information

Application

Bromfenac sodium has been used:
  • to study its ability to bind to melanin[1]
  • in the synthesis of bromfenac indolinone standard[2]
  • to analyze its permeability in porcine conjunctiva[3]

Biochem/physiol Actions

Bromfenac exhibits antipyretic and prostaglandin synthetase inhibiting properties.[4] It has therapeutic properties against the reduction of ocular pain and inflammation in postoperative cataract patients.[5] Bromfenac acts as an effective agent against allergic conjunctivitis.[4] It has the potential to treat acute muscle pain, osteoarthritis, and rheumatoid arthritis.[2]
Bromfenac is a nonsteroidal anti inflammatory drug (NSAID) that inhibits both COX1 and COX2. It is used as an opthalmic analgesic.
Bromfenac is a nonsteroidal anti inflammatory drug (NSAID); COX1 and COX2 inhibitor; opthalmic analgesic.

pictograms

Skull and crossbones

signalword

Danger

hcodes

Hazard Classifications

Acute Tox. 3 Oral

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Los clientes también vieron

Slide 1 of 1

1 of 1

Eiichi Uchio et al.
Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde, 221(3), 153-158 (2007-04-19)
We evaluated the efficacy and safety of long-term management of patients with vernal keratoconjunctivitis (VKC) with bromfenac sodium eye drops in combination with corticosteroids and anti-allergic eye drops. Twenty-two patients with VKC were randomly assigned to receive two test eye
Ester Carreño et al.
Clinical ophthalmology (Auckland, N.Z.), 6, 637-644 (2012-05-10)
Ophthalmic bromfenac sodium sesquihydrate is a topically applied selective cyclooxygenase (COX)-2 inhibitor. It is similar to amfenac, except for a bromine atom at the C(4) of the benzoyl ring position, which markedly affects its in vitro and in vivo potency
Neal A Sher et al.
Journal of refractive surgery (Thorofare, N.J. : 1995), 25(2), 214-220 (2009-02-27)
To compare the efficacy of two topical nonsteroidal anti-inflammatory drugs with regards to the control of pain, burning, photophobia, foreign body sensation, and epithelial healing rates in patients who underwent photorefractive keratectomy (PRK). Two hundred twelve eyes were randomized to
Jeffrey S Heier et al.
Retina (Philadelphia, Pa.), 29(9), 1310-1313 (2009-11-26)
To assess vitreous concentrations of nonsteroidal antiinflammatory drugs (NSAIDs) and prostaglandin E(2) in patients treated with NSAIDs before vitrectomy. This was an investigator-masked, randomized, multicenter study. Patients received ketorolac 0.4% 4 times a day, bromfenac 0.09% 2 times a day
Christina Flaxel et al.
Retina (Philadelphia, Pa.), 32(3), 417-423 (2011-08-25)
To evaluate whether bromfenac eyedrops and ranibizumab intravitreal injections would provide added efficacy over ranibizumab alone. This was a single-site, multiinvestigator, prospective, open-label, interventional, Phase II study of patients with new or recurrent exudative/neovascular age-related macular degeneration. Thirty eyes were

Questions

Reviews

No rating value

Active Filters

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico